Page last updated: 2024-11-13

1-eicosapentaenoylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

It seems you're asking about **1-eicosapentaenoylglycerol** (1-EPA-G). This is a **monoglyceride** containing the **omega-3 fatty acid eicosapentaenoic acid (EPA)**. Here's a breakdown of its key features and research significance:

**Structure and Properties:**

* **Monoglyceride:** 1-EPA-G consists of one molecule of glycerol (a three-carbon alcohol) with one EPA molecule attached to the first carbon position of glycerol.
* **EPA:** EPA is a long-chain polyunsaturated fatty acid (PUFA) with 20 carbon atoms and five double bonds. It's an essential fatty acid, meaning the human body cannot synthesize it and must obtain it through diet.
* **Hydrolyzable:** 1-EPA-G can be broken down into glycerol and EPA by enzymes called lipases.

**Research Significance:**

1-EPA-G is a focus of research for several reasons:

* **Potential Health Benefits:** EPA has been extensively studied for its potential health benefits, including:
* **Cardiovascular Health:** EPA may lower triglyceride levels, improve blood pressure, and reduce the risk of heart disease.
* **Inflammation:** EPA has anti-inflammatory properties and may be beneficial for conditions like arthritis.
* **Mental Health:** Studies suggest EPA may play a role in mood regulation and have potential benefits for depression.
* **Improved Bioavailability:** 1-EPA-G is believed to have improved bioavailability compared to EPA in its free fatty acid form. This means the body may be able to absorb and utilize EPA more effectively when it's in the form of 1-EPA-G.
* **Bioactive Properties:** 1-EPA-G itself has been shown to possess some unique bioactive properties, such as:
* **Antioxidant Activity:** 1-EPA-G may act as an antioxidant, protecting cells from damage.
* **Anti-cancer Effects:** Some studies suggest 1-EPA-G may have anti-cancer activity.

**Areas of Research:**

* **Dietary Supplements:** Researchers are exploring the use of 1-EPA-G as a dietary supplement to provide a more bioavailable source of EPA.
* **Pharmaceutical Applications:** 1-EPA-G is being investigated for its potential as a therapeutic agent for various diseases, particularly those linked to inflammation and cardiovascular health.
* **Food Science:** 1-EPA-G can be incorporated into food products to increase EPA content and improve nutritional value.

**Important Note:**

While 1-EPA-G shows promise, more research is needed to fully understand its benefits and risks. Always consult with a healthcare professional before using any supplements or making significant dietary changes.

1-eicosapentaenoylglycerol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID85540151
MeSH IDM0594149

Synonyms (1)

Synonym
1-eicosapentaenoylglycerol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]